e-learning
resources
Stockholm 2002
Tuesday 17.09.2002
Biological disease markers in airways and parenchymal lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Elevation of plasma cystatin C levels in patients with COPD
T. Nakajima, H. Nakamura, H. Tateno, N. Minematsu, S. Fujishima, K. Yamaguchi (Tokyo, Japan)
Source:
Annual Congress 2002 - Biological disease markers in airways and parenchymal lung disease
Session:
Biological disease markers in airways and parenchymal lung disease
Session type:
Poster Discussion
Number:
3604
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Nakajima, H. Nakamura, H. Tateno, N. Minematsu, S. Fujishima, K. Yamaguchi (Tokyo, Japan). Elevation of plasma cystatin C levels in patients with COPD. Eur Respir J 2002; 20: Suppl. 38, 3604
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Imaging of complicated pneumonia: what is new?
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
COPD patients with more severe GOLD stages have higher serum cystatin C levels
Source: Annual Congress 2012 - The smoking gun in COPD biology
Year: 2012
Serum lipid levels in patients with bronchiectasis
Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi
Year: 2008
Elevated serum inflammatory markers in patients with stable COPD
Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease
Year: 2009
Plasma levels of soluble RAGE are lower in COPD
Source: Annual Congress 2009 - COPD and asthma - from the cell to the clinic
Year: 2009
Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD
Source: International Congress 2017 – COPD biomarkers
Year: 2017
Plasma vitamin D concentration and clinical characteristics in clinically stable patients with moderate COPD
Source: Annual Congress 2011 - Physiological basis of respiratory disease
Year: 2011
Determinants of serum leptin and adiponectin levels in patients with COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 59s
Year: 2005
Serum vitamin D level is associated with emphysema progression in male patients with COPD
Source: International Congress 2017 – Markers of COPD progression
Year: 2017
Serum vitamin C level in patients with acute pneumonia and in COPD patients before and after therapy
Source: Eur Respir J 2006; 28: Suppl. 50, 38s
Year: 2006
Levels of serum amyloid A (SAA) and C-reactive protein (CRP) in stable COPD patients and its relationship with disease severity.
Source: International Congress 2017 – COPD biomarkers
Year: 2017
High serum levels of YKL-40 in IPF
Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology
Year: 2008
Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
Elevated serum S100A4 levels in patients with silicosis
Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis
Year: 2019
Serum neopterin and IL-6 as biomarkers in patients with COPD.
Source: International Congress 2017 – Novel molecular and genetic targets in COPD
Year: 2017
Relation of low serum lipid levels with coronary atherosclerosi in COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 662s
Year: 2006
Serum TNFα, CD14 and CRP levels in COPD patients with different alpha-1 antitrypsin phenotypes
Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases
Year: 2008
Magnesium levels in erythrocytes and plasma in patients with exacerbated COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 429s
Year: 2001
Elevated blood neutrophil levels in GOLD 2017 COPD group D – results from the TIE-study
Source: International Congress 2017 – Markers of COPD progression
Year: 2017
C-reactive protein serum levels, genotypes and the risk of COPD. The Rotterdam study
Source: Annual Congress 2008 - Genetic risk factors for asthma and COPD
Year: 2008
Asthmatics with high levels of serum surfactant protein D have more severe disease
Source: Eur Respir J 2016; 47:1864-1867
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept